ArticleMucosal immunology2025

Tofacitinib ameliorates Campylobacter-induced intestinal pathology by suppressing IFNγ producing ILCs and T cells.

Anna A Korchagina et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.